<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165774</url>
  </required_header>
  <id_info>
    <org_study_id>EK 2012 0048</org_study_id>
    <nct_id>NCT02165774</nct_id>
  </id_info>
  <brief_title>Sacral Neuromodulation for Neurogenic LUT Dysfunction</brief_title>
  <official_title>Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, placebo-controlled, double-blind multicenter trial including 4
      tertiary sacral neuromodulation referral centers in Switzerland (Z端rich, Bern, Nottwil,
      St.Gallen). Patients with refractory neurogenic LUTD are included and randomized after
      neuromodulator implantation into sacral neuromodulation ON or sacral neuromodulation OFF
      (n=30) for a 2 months double-blind phase. In addition to standard neuro-urological
      assessments, patients who agree will also undergo neurophysiological investigation of the
      lower urinary tract, i.e. recording of current perception thresholds, sensory evoked
      potentials, and electroencephalography after stimulation of the urethra and bladder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with successful sacral neuromodulation</measure>
    <time_frame>2 months</time_frame>
    <description>success versus failure (yes/no variable)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Refractory Neurogenic LUTD</condition>
  <arm_group>
    <arm_group_label>sacral neuromodulation ON</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active sacral neuromodulation (neuromodulator ON)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sacral neuromodulation OFF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo sacral neuromodulation (neuromodulator OFF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Turning OFF the neuromodulator</intervention_name>
    <description>Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.</description>
    <arm_group_label>sacral neuromodulation OFF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Turning ON the neuromodulator</intervention_name>
    <arm_group_label>sacral neuromodulation ON</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory neurogenic LUTD

          -  Urgency frequency syndrome and/or urgency incontinence refractory to antimuscarinics
             (pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics)

          -  Chronic urinary retention refractory to alpha-blocker (pharmacotherapy with an
             alpha-blocker for at least 4 weeks)

          -  Combination of urgency frequency syndrome and/or urgency incontinence and chronic
             urinary retention refractory to antimuscarinics (pharmacotherapy for at least 4 weeks
             with at least 2 antimuscarinics) and alpha-blocker (pharmacotherapy with an
             alpha-blocker for at least 4 weeks)

          -  Stable neurological disease/injury for at least 12 months

          -  Age minimum 18 years

          -  Informed consent

        Exclusion Criteria:

          -  Botulinum A toxin injections into the detrusor and/or urethral sphincter in the last
             6 months

          -  Age under 18 years

          -  Pregnancy

          -  Individuals especially in need of protection (according to Research with Human
             Subjects published by the Swiss Academy of Medical Sciences)

          -  No informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas M. Kessler, PD Dr. med.</last_name>
    <phone>+41 44 386 3907</phone>
    <email>thomas.kessler@balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Kn端pfer, Dr. med.</last_name>
    <phone>+41 44 386 3721</phone>
    <email>sknuepfer@paralab.balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre Nottwil</name>
      <address>
        <city>Nottwil</city>
        <state>Luzern</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J端rgen Pannek, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Inselspital Berne</name>
      <address>
        <city>Berne</city>
        <zip>3000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Burkhard, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Engeler, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Zurich, Balgrist University Hospital, Spinal Cord Injury Center</name>
      <address>
        <city>Zurich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas M. Kessler, PD Dr. med.</last_name>
      <phone>+41 44 386 3907</phone>
      <email>thomas.kessler@balgrist.ch</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Kn端pfer, Dr. med.</last_name>
      <phone>+41 44 386 3721</phone>
      <email>sknuepfer@paralab.balgrist.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>June 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sacral neuromodulation, neurogenic lower urinary tract dysfunction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
